Neoadjuvant cobimetinib and atezolizumab with or without vemurafenib for stage III melanoma: outcomes and the impact of the microbiome from the NeoACTIVATE trial

Background Neoadjuvant treatment has become standard for patients with high-risk operable stage III melanoma, but the optimal regimen is unknown. Targeted therapy approaches yield high pathological response rates, while immunotherapy regimens show favorable recurrence-free survival (RFS). NeoACTIVAT...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Jun Chen, Stephen Johnson, Haidong Dong, Evidio Domingo-Musibay, Matthew S Block, David Zahrieh, Lu Yang, Robert R McWilliams, Svetomir N Markovic, Tina J Hieken, Jane Yuet Ching Hui, Anastasios Dimou, Eric P Grewal, Courtney L Erskine, Garth D Nelson, Thomas James Flotte, Lisa A Kottschade, Heather N Montane, Mara A Piltin, Daniel L Price, Samir S Khariwala, Carrie A Strand
Formato:	Artigo
Idioma:	Inglês
Publicado em:	BMJ Publishing Group 2025-04-01
coleção:	Journal for ImmunoTherapy of Cancer
Acesso em linha:	https://jitc.bmj.com/content/13/4/e011706.full
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!